In COVID-19 clinical update #107, Daniel Griffin reviews vaccine booster doses, at-home testing, transmission in ferrets, improving indoor air quality, trials of BCG, ivermectin, and fluvoxamine, vaccination during pregnancy, mRNA vaccines and Fc functions, anti-platelet and aspirin therapy and a trial of prone positioning.

Vincent and Brianne review the need to better understand T cell responses to SARS-CoV-2 infection to better inform public health decisions, and how IL-1 and IL-1ra are important regulators of the inflammatory response to RNA vaccines.

TWiV describes the identification of a monoclonal antibody that provides broad protection against a variety of hantaviruses, and development of an oral remdesivir-like antiviral that ameliorates viral disease in mice.

In COVID-19 clinical update #107, Daniel Griffin discusses Moderna vaccine results in children, hospitalization by ethnicity, BA.2 severity in children, placentitis and thrombohematoma during pregnancy, predictive value of symptoms for diagnosis, Evusheld activity against BA.1 and BA.2, Remdesivir resistance, Ivermectin with and without strongyloidiasis, inhaled ciclesonide, home telemonitoring, pulse oximetry for remote monitoring, effectiveness of anti-platelet therapy, and deaths in Zambia.

In COVID-19 clinical update #106, Daniel Griffin covers failure of ivermectin to improve hospitalization, increased hospitalization of children with Omicron, seroconversion of children versus adults, effectiveness of Pfizer mRNA vaccine in children, high vaccine effectiveness in Finland against Omicron, distinct long COVID clinical phenotypes, and estimating worldwide excess mortality.

TWiV discusses the virome of game animals in China, and the finding that binding of sarbecoviruses to ACE2 is an ancestral and evolvable trait.